These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29985967)

  • 1. Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign.
    Alshora DH; Ibrahim MA; Elzayat E; Almeanazel OT; Alanazi F
    PLoS One; 2018; 13(7):e0200218. PubMed ID: 29985967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the process parameters affecting the fabrication of rosuvastatin calcium nanoparticles by planetary ball mill.
    Alshora D; Ibrahim M; Elzayat E; Almeanazel OT; Alanazi F
    Int J Nanomedicine; 2019; 14():4625-4636. PubMed ID: 31303752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
    Patel PJ; Gajera BY; Dave RH
    Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-stabilization of pioglitazone HCL nanoparticles prepared by planetary ball milling:
    Alshora DH; Alsaif S; Ibrahim MA; Ezzeldin E; Almeanazel OT; Abou El Ela AES; Ashri LY
    Pharm Dev Technol; 2020 Sep; 25(7):845-854. PubMed ID: 32174213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxylate cross-linked cyclodextrin: A nanoporous scaffold for enhancement of rosuvastatin oral bioavailability.
    Gabr MM; Mortada SM; Sallam MA
    Eur J Pharm Sci; 2018 Jan; 111():1-12. PubMed ID: 28931488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro/in vivo evaluation of felodipine micropowders prepared by the wet-milling process combined with different solidification methods.
    Meng J; Li S; Yao Q; Zhang L; Weng Y; Cai C; Xu H; Tang X
    Drug Dev Ind Pharm; 2014 Jul; 40(7):929-36. PubMed ID: 23614872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized Nanoparticles for Enhanced Oral Bioavailability of a Poorly Soluble Drug: Solid Lipid Nanoparticles Versus Nanostructured Lipid Carriers.
    Darwish MKM; El-Enin ASMA; Mohammed KHA
    Pharm Nanotechnol; 2022; 10(1):69-87. PubMed ID: 35142275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
    Patel GV; Patel VB; Pathak A; Rajput SJ
    Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of Hydroxypropyl Methylcellulose and Dextrin in Development of Dried Nanosuspension for Poorly Water-Soluble Drug.
    Heo EJ; Park SY; Kim HI; Sung JH; Kwon HJ; Jee JP; Maeng HJ; Cho KH; Kim ST; Kim YC; Choi SU; Jang DJ
    J Nanosci Nanotechnol; 2020 Sep; 20(9):5813-5818. PubMed ID: 32331187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
    Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies.
    Dudhipala NR; Ettireddy SR; Puchakayala GR
    Chem Phys Lipids; 2021 Jul; 237():105081. PubMed ID: 33811848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.
    Alshweiat A; Katona G; Csóka I; Ambrus R
    Eur J Pharm Sci; 2018 Sep; 122():94-104. PubMed ID: 29908301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of Formulation and Process Parameters of Wet Media Milling to Develop Etodolac Nanosuspensions.
    Karakucuk A; Celebi N
    Pharm Res; 2020 May; 37(6):111. PubMed ID: 32476048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz Dissolution Enhancement IV-Antisolvent Nanocrystallization by Sonication, Physical Stability, and Dissolution.
    Sartori GJ; Prado LD; Rocha HVA
    AAPS PharmSciTech; 2017 Nov; 18(8):3011-3020. PubMed ID: 28493004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK; Patel MH; Patel K
    Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
    Mou D; Chen H; Wan J; Xu H; Yang X
    Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexagonal Liquid Crystalline Nanodispersions Proven Superiority for Enhanced Oral Delivery of Rosuvastatin: In Vitro Characterization and In Vivo Pharmacokinetic Study.
    Gabr MM; Mortada SM; Sallam MA
    J Pharm Sci; 2017 Oct; 106(10):3103-3112. PubMed ID: 28479357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Process and Formulation Parameters on the Fabrication of Efavirenz Nanosuspension to Improve Drug Solubility and Dissolution.
    Rashed M; Dadashzadeh S; Bolourchian N
    Iran J Pharm Res; 2022 Dec; 21(1):e129409. PubMed ID: 36942076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of optimized sucrose ester stabilized oleanolic acid nanosuspensions prepared by wet ball milling with design of experiments.
    Li W; Ng KY; Heng PW
    Biol Pharm Bull; 2014; 37(6):926-37. PubMed ID: 24882406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and drying of miconazole and itraconazole nanosuspensions.
    Cerdeira AM; Mazzotti M; Gander B
    Int J Pharm; 2013 Feb; 443(1-2):209-20. PubMed ID: 23291552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.